NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, off-the-shelf, immune-modulating therapeutic cancer vaccines based ...

Already this year, we delivered multiple high-value phase 3 readouts. LAURA expands the reach of Tagrisso in early stage lung cancer. Calquence advances into mantle cell lymphoma with ECHO, and with ...